Tumor mutational burden and PTEN alterations as molecular correlates of response to PD-1/L1 blockade in metastatic triple-negative breast cancer

PURPOSE: Few patients with metastatic triple-negative breast cancer (mTNBC) benefit from immune checkpoint inhibitors (ICIs). Based on immunotherapy response correlates in other cancers, we evaluated whether high tumor mutational burden (TMB) ≥10 nonsynonymous mutations/megabase and PTEN alterations...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Main Authors: Barroso-Sousa, Romualdo, Keenan, Tanya E., Pernas, Sonia, Exman, Pedro, Jain, Esha, Garrido-Castro, Ana C., Hughes, Melissa, Bychkovsky, Brittany, Umeton, Renato, Files, Janet L., Lindeman, Neal I., MacConaill, Laura E., Hodi, F. Stephen, Krop, Ian E., Dillon, Deborah, Winer, Eric P., Wagle, Nikhil, Lin, Nancy U., Mittendorf, Elizabeth A., Van Allen, Eliezer M., Tolaney, Sara M.
Formato: Artigo
Idioma:Inglês
Publicado: 2020
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7269810/
https://ncbi.nlm.nih.gov/pubmed/32019858
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-3507
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares